Skip to search formSkip to main contentSkip to account menu

Recombinant interferon beta-1a

Known as: INTERFERON BETA-1A,RECOMBINANT, Interferon Beta-1A 
A synthetic version of naturally occurring interferons that have immunomodulatory, antiviral and antiproliferative activities. It may exert antitumor… 
National Institutes of Health

Related topics

Related topics

38 relations
Acquired Immunodeficiency SyndromeAge related macular degenerationAutoimmune DiseasesBrain Neoplasms

Narrower (1)

Rebif

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Clinical effects and tolerability of high-dose, high-frequency recombinant interferon β-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence
Importance of the field: High-dose, high-frequency IFN β-1a in multiple sclerosis (MS) can prevent lesion formation, decrease the… 
Review
2009
Review
2009
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis.
BACKGROUND There is at present no cure for multiple sclerosis (MS), and existing therapies are designed primarily to prevent… 
Review
2009
Review
2009
High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis
Background: There is at present no cure for multiple sclerosis (MS), and existing therapies are designed primarily to prevent… 
2009
2009
AGE-RELATED CHANGES IN MOTOR SUBTLE SIGNS AMONG GIRLS AND BOYS WITH ADHD
Fenstermacher JD. In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with… 
Highly Cited
2005
Highly Cited
2005
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment
Matrix metalloproteinase-9 (MMP-9) is involved in blood-brain barrier (BBB) disruption in active multiple sclerosis (MS), while… 
2002
2002
Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.
Although effective conventional therapies are available to treat basal cell carcinoma (BCC), undesirable side effects, including… 
2000
2000
A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C.
AIMS Interferon alpha monotherapy induces a sustained response in less than 20% of patients treated for chronic hepatitis C… 
1995
1995
A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients…
The design and conduct of a randomized, double-blinded, placebo-controlled, multicenter, phase III study of recombinant… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)